COPD Insights for Primary Care: 5 New Studies

Moderna's mRNA-1283 vaccine gains FDA approval for high-risk groups, following a significant shift in COVID-19 vaccination guidelines by federal health agencies.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.